Elite Pharma Inc (ELTP)

Currency in USD
0.2889
+0.0009(+0.31%)
Closed·
Advertisement
Unusual trading volume
ELTP is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.28740.2995
52 wk Range
0.27200.7200
Key Statistics
Prev. Close
0.288
Open
0.2995
Day's Range
0.2874-0.2995
52 wk Range
0.272-0.72
Volume
1.93M
Average Volume (3m)
758.29K
1-Year Change
-57.8936%
Book Value / Share
0.1
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ELTP Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
RSI suggests the stock is in oversold territory

Elite Pharma Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Neutral

Elite Pharma Inc Earnings Call Summary for Q1/2027

  • Elite Pharmaceuticals reported Q1 FY2027 revenue of $32.4M, down YoY due to normalization after premium-priced lisdexamfetamine launch.
  • Operating profit reached $7.5M with 23.1% margin; cash balance rose to $38.9M from $29.8M, demonstrating strong liquidity despite pricing pressure.
  • Volume grew 14.75% YoY with market share gains across major products; launched methadone in April and buprenorphine formulation in July.
  • Shares fell 11.38% to $0.3177, trading 57% below 52-week high as investors focused on revenue decline over margin strength and cash generation.
  • Management targets anticonvulsant ANDA filing in Q1 2027, anticoagulant launch in 2028, facility expansion, and Nasdaq uplisting by early 2027.
Last Updated: 14/08/2026, 20:02
Read Full Transcript

Earnings

Latest Release
29/06/2026
EPS / Forecast
0.01 / --
Revenue / Forecast
40.75M / --
EPS Revisions
Last 90 days

Compare ELTP to Peers and Sector

Metrics to compare
ELTP
Peers
Sector
Relationship
P/E Ratio
5.5x2.9x−0.4x
PEG Ratio
0.01−0.180.00
Price/Book
3.0x2.6x2.6x
Price / LTM Sales
2.2x1.9x3.1x
Upside (Analyst Target)
-38.0%48.1%
Fair Value Upside
Unlock2.3%6.3%Unlock

Elite Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development, manufacture, and sale of oral, controlled-release products, and generic pharmaceuticals. It owns, licenses, manufactures, and sales of generic, oral dose pharmaceuticals products, such as Phentermine HCl 37.5mg tablets, and 15mg and 30mg capsules to treat bariatrics under Adipex-P brand; Phendimetrazine Tartrate 35mg tablets for bariatrics under the Bontril brand; Naltrexone HCl 50mg tablets for the treatment of pains under the Revia brand; and Isradipine 2.5mg and 5mg capsules for cardiovascular diseases. It also provides Trimipramine Maleate Immediate Release antidepressant capsules under the Surmontil brand; Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Immediate Release tablets under the Adderall brand; Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate Extended Release capsules under the Adderall XR brand for central nervous system diseases; Dantrolene Sodium capsules for muscle relaxant under the Dantrium brand; Methotrexate Sodium 2.5mg tablets for the treatment of Antimetabolite under the Otrexup PF brand; Loxapine Succinate capsules for treating antipsychotic under the Loxapine brand; Acetaminophen and Codeine Phosphate for the management of mild to moderate pain; Acetaminophen and Hydrocodone Bitartrate capsules for the treatment of pain under the Norco brand; Lisdexamfetamine Dimesylate to treat ADHD under the Vyvanse brand; Oxycodone Hydrochloride and Acetaminophen tablets to treat pain under the Percocet brand name; and Methadone Hydrochloride tablets for the treatment of pain under the Dolophine brand. In addition, it manufactures controlled-release products on a contract basis for third parties in the areas of allergy, bariatric, attention deficit, and infection. The company was incorporated in 1997 and is headquartered in Northvale, New Jersey.

Employees
65

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
0.000.00%0.00
Other Institutional Investors
1.00K0.00%288.85
Public Companies & Retail Investors
1.11B100.00%320.94M
Total
1.11B100.00%320.94M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Kelleher Financial Advisors, LLC0.00%1,0000

People Also Watch

199.84
SENEA
+3.96%
24.180
SPNT
+0.46%
14.21
NATR
+2.08%
4.30
BUKS
+1.18%

FAQ

What Is the Elite Pharma Inc (OTC Markets: ELTP) Share Price Today?

The Elite Pharma Inc stock price today is 0.2889 USD.

What Stock Exchange Does Elite Pharma Inc (ELTP) Trade On?

Elite Pharma Inc is listed and trades on the OTC Markets.

What Is the Ticker (Stock Symbol) for Elite Pharma Inc?

The stock symbol (also called a 'ticker') for Elite Pharma Inc is "ELTP."

What Is the Current Elite Pharma Inc Market Capitalisation?

As of today, Elite Pharma Inc (OTC Markets: ELTP) market cap is 311.1300M USD.

What Is Elite Pharma Inc's (ELTP) Earnings Per Share (TTM)?

The Elite Pharma Inc EPS is currently 0.0439 (Trailing Twelve Months).

Is ELTP a Buy or Sell From a Technical Analyst Perspective?

Based on today's Elite Pharma Inc moving averages and other technical indicators, the daily buy/sell signal for ELTP stock is Strong Sell.

How Many Times Has Elite Pharma Inc Stock Split?

Elite Pharma Inc has split 2 times. (See the ELTP stock split history page for full effective split date and price information.)

How Many Employees Does Elite Pharma Inc Have?

Elite Pharma Inc has 65 employees, based on their latest Companies House report.

What is the current trading status of Elite Pharma Inc (OTC Markets: ELTP)?

As of 30/08/2026, Elite Pharma Inc (ELTP) is trading at a share price of 0.2889 USD, with a previous close of 0.2880 USD. The stock has fluctuated within a day range of 0.2874 USD to 0.2995 USD, while its 52-week range spans from 0.2720 USD to 0.7200 USD.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.